Diretriz para análises de impacto orçamentário de tecnologias em saúde no Brasil

Budget impact analysis (BIA) provides operational financial forecasts to implement new technologies in healthcare systems. There were no previous specific recommendations to conduct such analyses in Brazil. This paper reviews BIA methods for health technologies and proposes BIA guidelines for the public and private Brazilian healthcare system. The following recommendations were made: adopt the budget administrator's perspective; use a timeframe of 1 to 5 years; compare reference and alternative scenarios; consider the technology's rate of incorporation; estimate the target population by either an epidemiological approach or measured demand; consider restrictions on technologies' indication or factors that increase the demand for them; consider direct and averted costs; do not adjust for inflation or discounts; preferably, integrate information on a spreadsheet; calculate the incremental budget impact between scenarios; and summarize information in a budget impact report.

[1]  M. Drummond,et al.  Guidelines for Conducting Pharmaceutical Budget Impact Analyses for Submission to Public Drug Plans in Canada , 2012, PharmacoEconomics.

[2]  T. Mittendorf,et al.  Practical issues in handling data input and uncertainty in a budget impact analysis , 2010, The European Journal of Health Economics.

[3]  E. Orlewska,et al.  Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[4]  Mark Nuijten,et al.  Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[5]  Budget impact analyses get some respect. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[6]  J R Beck,et al.  Markov Models in Medical Decision Making , 1993, Medical decision making : an international journal of the Society for Medical Decision Making.

[7]  Brasil. Ministério da Ciência,et al.  Diretrizes metodológicas: estudos de avaliação econômica de tecnologias em saúde , 2009 .

[8]  L. Gulácsi,et al.  Budget-Impact Analyses , 2012, PharmacoEconomics.

[9]  Departamento de Ciência e Technologia [Health Technology Assessment: institutionalization of actions in the Brazilian Ministry of Health]. , 2006, Revista de saude publica.

[10]  S. Wilson Methods for the economic evaluation of health care programmes , 1987 .

[11]  F. Rutten,et al.  Combining a Budgetary-Impact Analysis and a Cost-Effectiveness Analysis Using Decision-Analytic Modelling Techniques , 2012, PharmacoEconomics.